Date: August 23 and 24, 2024
Format: In person
Local: Sirio-Libanês Ensino e Pesquisa | Rua Professor Daher Cutait, 69 - Bela Vista
Coordination:
• Dra. Maria Cristina Seiwald
• Dra. Yana Novis
Presentation:
TThe International Conference on Updates in Onco-Hematology and Cell Therapy aims to bring the latest in these areas, which have seen great scientific progress in recent years. It aims to promote the exposition and debate of themes, in addition to encouraging interaction between participants and speakers.
The event will address the latest and most relevant advances in these fields, issues that directly impact the day-to-day clinical care, presenting and discussing them with a critical view on the subject.
There will be the opportunity to witness and interact with international and national speakers, professionals who are world references in areas of hematology, such as acute leukemias, chronic lymphoproliferative diseases, lymphomas, plasma cell neoplasms, bone marrow transplantation and CAR-T cells.
Target Audience:
• Physicians specializing in hematology, onco-hematology and bone marrow transplantation
Goals:
• Update in Hematology, focusing on onco-hematology
• Bone marrow transplant
• Cell therapy
Differentials:
• International Speakers
• Interactive classes
Certificates: The certificate will be released within 15 days after the event, on the registration platform.
Maria Cristina N. Seiwald, MD
Yana Novis, MD
| Schedule: Friday, August 23th 2024
*Programming subject to changes and guest confirmations |
|
| 12:00 – 12:50 | Registration In-Person: Ensino e Pesquisa Sírio-Libanês, São Paulo |
| 12:50 – 13:00 | Opening |
| Session: Celullar Therapy | |
| 13:00 – 13:20 |
TBD |
| 13:20 – 13:40 |
TBD |
| 13:40 – 14:00 | Q&A |
| Session: Debate CAR-T Cells vs BMT | |
| 14:00 – 14:30 | CAR-T in second line for diffuse large B cell lymphoma |
| 14:30 – 14:50 | Auto BMT in second line for diffuse large B cell lymphoma |
| 14:50 – 15:20 | Q & A |
| 15:20 – 16:10 | Satellite Symposium |
| 16:10 – 16:40 | Coffee Break |
| Session: Question and Answers – Difficult Case – High Grade Lymphomas | |
| 16:40 – 17:00 | AR-T for lymphoma |
| 17:00 – 17:20 | Biespecifics for lymphoma |
| 17:20 – 17:40 | Q&A |
| Session: Monoclonal Gammopathies | |
| 17:40 - 18:00 | MRD directed therapy in MM: are we ready? |
| 18:00 – 18:20 | High risk myeloma: who and how to treat these patients? |
| 18:20 – 18:40 | Relapse refractory MM: how to choose best therapy – CAR-T vs Biespecifics |
| 18:40 – 19:00 | Q&A |
| Schedule: Saturday, August 24th 2024
*Programming subject to changes and guest confirmations |
|
| Session: AML/MDS | |
| 08:40 – 09:00 |
First-line therapy for high-risk MDS |
| 09:00 – 09:20 |
AML: beyond 3+7 |
| 09:20 – 09:40 | Treatment options for patients with relapsed, refractory or persistent AML |
| 09:40 – 10:00 | Q&A |
| 10:00 – 10:30 | Break |
| Session: Question and Answers – Difficult Clinical Cases - Lymphomas | |
| 10:30 – 11:00 | Follicular Lymphoma: relapse |
| 11:00 – 11:30 | Mantle cell lymphoma: First line therapy |
| 11:30 – 11:50 | Q&A |
| 11:50 – 12:30 | Satellite Symposium |
| 12:30 – 13:30 | Lunch Break |
| Session: Debate CLL | |
| 13:30 – 14:00 | BTKi vs BCL2 in frontline CLL |
| 14:00 – 14:30 | BTKi vs BCL2 in frontline CLL |
| 14:30 – 15:00 | Q&A |
| Session: LLA | |
| 15:00 – 15:20 | Immunotherapy in ALL |
| 15:20 – 15:40 | CAR-T for ALL – bridge or definite therapy? |
| 15:40 – 16:00 | Advances in Ph-like ALL |
| 16:00 – 16:20 | Q&A |
| 16:20 – 16:50 | Break |
| Session: Myeloproliferative Diseases | |
| 16:50 - 17:20 | MApproach of P. Vera and ET in 2024 |
| 17:20 - 17:50 | Current treatment of myelofibrosis and indication of BMT |
| 17:50 – 18:10 | Q&A |
| 18:00 | Closure |